Article
Rheumatology
Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp
Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Multidisciplinary Sciences
Ian R. White, Sarah E. Kleinstein, Christophe Praet, Chris Chamberlain, Duncan McHale, Jessica M. Maia, Pingxing Xie, David B. Goldstein, Thomas J. Urban, Patrick R. Shea
Summary: This study aimed to identify genetic variants predictive of CZP response, but did not find a clear predictor of CZP response.
Article
Medicine, General & Internal
Nicolino Ruperto, Hermine Brunner, Olga Synoverska, Tracy Ting, Carlos Abud Mendoza, Alberto Spindler, Yulia Vyzhga, Katherine Marzan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Rita Jerath, Daniel J. Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Yonatan Butbul Aviel, Vyacheslav Chasnyk, Melissa Lerman, Kabita Nanda, Heinrike Schmeling, Heather Tory, Yosef Uziel, Diego O. Viola, Holly B. Posner, Keith S. Kanik, Ann Wouters, Cheng Chang, Richard Zhang, Irina Lazariciu, Ming-Ann Hsu, Ricardo M. Suehiro, Alberto Martini, Daniel J. Lovell
Summary: The trial showed that tofacitinib is an effective treatment for patients with polyarticular course JIA. New oral therapies are particularly relevant for children and adolescents, who might prefer to avoid injections.
Article
Rheumatology
Walter P. Maksymowych, Thomas Kumke, Simone E. Auteri, Bengt Hoepken, Lars Bauer, Martin Rudwaleit
Summary: In non-radiographic axial spondyloarthritis (nr-axSpA) patients, younger age and male sex are predictors of clinical response at Week 12 in patients treated with certolizumab pegol (CZP). For long-term clinical response at Week 52, sacroiliitis on MRI and HLA-B27 positivity are consistent predictors across multiple efficacy outcomes in CZP-treated patients.
ARTHRITIS RESEARCH & THERAPY
(2021)
Article
Medicine, General & Internal
Athimalaipet Ramanan, Pierre Quartier, Nami Okamoto, Ivan Foeldvari, Alberto Spindler, Sarka Fingerhutova, Jordi Anton, Zhongkai Wang, Gabriella Meszaros, Joana Araujo, Ran Liao, Stuart Keller
Summary: Baricitinib demonstrated good efficacy and acceptable safety in the treatment of polyarticular juvenile idiopathic arthritis, extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.
Article
Rheumatology
Maria C. Cid, Sebastian H. Unizony, Daniel Blockmans, Elisabeth Brouwer, Lorenzo Dagna, Bhaskar Dasgupta, Bernhard Hellmich, Eamonn Molloy, Carlo Salvarani, Bruce C. Trapnell, Kenneth J. Warrington, Ian Wicks, Manoj Samant, Teresa Zhou, Lara Pupim, John F. Paolini
Summary: This study evaluated the efficacy of the GM-CSF receptor antagonist mavrilimumab in maintaining disease remission in patients with giant cell arteritis. The results showed that mavrilimumab plus prednisone was superior to placebo plus prednisone in terms of time to flare and sustained remission.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Stephanie Ferrero, Ruth Wittoek, Edem Allado, Coralie Cruzel, Eric Fontas, Veronique Breuil, Liana Ziegler, Joel Kremer, Damien Loeuille, Christian H. Roux
Summary: The study found that weekly doses of 10-mg MTX did not show superiority over the placebo in terms of pain relief at 3 or 12 months, but may have some impact on structural progression. Synovitis on MRI could be associated with the erosive structural evolution of joints.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2021)
Article
Dermatology
Annunziata Dattola, Laura Vollono, Maria Cannizzaro, Raffaele D. Caposiena Caro, Sara Mazzilli, Gennaro Melino, Eleonora Candi, Elena Campione, Luca Bianchi
Summary: The study found that certolizumab pegol effectively improved both cutaneous and rheumatic disease in patients with mild psoriasis and psoriatic arthritis, with significant reductions in DAS44-ESR, PASI, and PAIN VAS from baseline to week 52.
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Medicine, General & Internal
Iain B. McInnes, Akihiko Asahina, Laura C. Coates, Robert Landewe, Joseph F. Merola, Christopher Ritchlin, Yoshiya Tanaka, Laure Gossec, Alice B. Gottlieb, Richard B. Warren, Barbara Ink, Deepak Assudani, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Philip J. Mease
Summary: This study evaluated the efficacy and safety of Bimekizumab in patients with active psoriatic arthritis who were naive to biologic DMARDs. The results showed that Bimekizumab treatment had superior improvements in joint, skin, and radiographic efficacy outcomes compared with placebo, and the safety profile was consistent with previous studies.
Article
Rheumatology
Desiree van der Heijde, Lianne S. Gensler, Walter P. Maksymowych, Robert Landewe, Martin Rudwaleit, Lars Bauer, Thomas Kumke, Mindy Kim, Simone Emanuele Auteri, Bengt Hoepken, Atul Deodhar
Summary: The 52-week results from the C-axSpAnd study demonstrate the long-term safety and efficacy of Certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). CZP treatment for up to 3 years is well tolerated and leads to sustained clinical improvement.
Article
Medicine, General & Internal
Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, Desiree van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L. Pangan, Peter Wung, In-Ho Song
Summary: Upadacitinib demonstrates significant efficacy and safety in patients with non-radiographic axial spondyloarthritis.
Article
Education & Educational Research
P. E. Brewer, M. Racy, M. Hampton, F. Mushtaq, J. E. Tomlinson, F. M. Ali
Summary: Technological advances in higher education, such as MOOCs and online learning, have brought accessibility and availability, but simply transferring educational material online may not ensure high quality learning. This study aimed to assess the role of technology in teaching clinical examination of the shoulder to medical students. Results showed that face-to-face teaching was the most effective method, while online platforms could be valuable for in-depth data analysis and improving the design of educational materials.
BMC MEDICAL EDUCATION
(2021)
Article
Rheumatology
Maarten Boers, Linda Hartman, Daniela Opris-Belinski, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Eduard N. Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, L. Thomas Klausch, Sabrina Paolino, Annemarie M. Schilder, Willem F. Lems, Maurizio Cutolo
Summary: This study compared the effects and side effects of low-dose prednisolone and placebo treatment in elderly patients with active rheumatoid arthritis. The results showed that low-dose prednisolone can reduce disease activity and joint damage, but the side effects also increased by 24%.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Dzenan Masic, Kristian Stengaard-Pedersen, Brian Bridal Logstrup, Kim Horslev-Petersen, Merete Lund Hetland, Peter Junker, Mikkel ostergaard, Christian Ammitzboll, Soren Moller, Robin Christensen, Torkell Ellingsen
Summary: In patients with rheumatoid arthritis, there were no significant differences in lipid level changes between those treated with adalimumab plus methotrexate and those treated with placebo plus methotrexate over a 1-year period. The study suggests that both treatment strategies have similar effects on lipid levels in early and treatment-naive RA patients.
RHEUMATOLOGY INTERNATIONAL
(2021)
Article
Clinical Neurology
Christa Walgaard, Bart C. Jacobs, Hester F. Lingsma, Ewout W. Steyerberg, Bianca van den Berg, Alexandra Y. Doets, Sonja E. Leonhard, Christine Verboon, Ruth Huizinga, Judith Drenthen, Samuel Arends, Ilona Kleine Budde, Ruud P. Kleyweg, Krista Kuitwaard, Marjon F. G. van der Meulen, Johnny P. A. Samijn, Frederique H. Vermeij, Jan B. M. Kuks, Gert W. van Dijk, Paul W. Wirtz, Filip Eftimov, Anneke J. van der Kooi, Marcel P. J. Garssen, Cees J. Gijsbers, Maarten C. de Rijk, Leo H. Visser, Roderik J. Blom, Wim H. J. P. Linssen, Elly L. van der Kooi, Jan J. G. M. Verschuuren, Rinske van Koningsveld, Rita J. G. Dieks, H. Job Gilhuis, Korne Jellema, Taco C. van der Ree, Henriette M. E. Bienfait, Catharina G. Faber, Harry Lovenich, Baziel G. M. van Engelen, Rutger J. Groen, Ingemar S. J. Merkies, Bob W. van Oosten, W. Ludo van der Pol, Willem D. M. van der Meulen, Umesh A. Badrising, Martijn Stevens, Albert-Jan J. Breukelman, Casper P. Zwetsloot, Maaike M. van der Graaff, Marielle Wohlgemuth, Richard A. C. Hughes, David R. Cornblath, Pieter A. van Doorn
Summary: The study indicates that a second intravenous immunoglobulin course is not effective for Guillain-Barre syndrome patients with a poor prognosis, and may lead to serious adverse events. Therefore, it should be avoided in the treatment of Guillain-Barre syndrome.
Letter
Rheumatology
Anna Molto, Desiree van der Heijde, Filip E. van den Bosch, Maxime Dougados
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Ricardo J. O. Ferreira, Paco M. J. Welsing, Johannes W. G. Jacobs, Laure Gossec, Mwidimi Ndosi, Pedro M. Machado, Desiree van der Heijde, Jose A. P. Da Silva
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou
Summary: This study aims to provide updated evidence on the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) for the revision of management recommendations. The results showed significant efficacy of tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i), while IL-23 inhibitors failed to demonstrate relevant effects. Observational studies are required to confirm the long-term safety of IL-17i.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Review
Rheumatology
Augusta Ortolan, Casper Webers, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou
Summary: This study updated the evidence of non-biological treatments for axSpA, providing a basis for the 2022 ASAS-EULAR recommendations. The results showed that education, exercise, and NSAIDs were efficacious in axSpA.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Augusta Ortolan, Sofia Ramiro, Roberta Ramonda, Desiree van der Heijde
Summary: The altASDAS index is a valid tool for assessing disease activity in axial SpA patients when patient global assessment is unavailable. It has been shown to be both truthful and discriminative in an external cohort, demonstrating its usefulness in clinical practice.
Review
Rheumatology
Dafne Capelusnik, Diego Benavent, Desiree van der Heijde, Robert Landewe, Denis Poddubnyy, Astrid van Tubergen, Louise Falzon, Victoria Navarro-Compan, Sofia Ramiro
Summary: This study conducted a systematic literature review to summarize the relationship between early treatment and treatment clinical response in patients with SpA. It found that early treatment was associated with better outcomes in patients with non-radiographic axSpA and symptom duration of less than 5 years, but no differences in response to treatment were found in radiographic axSpA or in patients with longer symptom duration.
Article
Rheumatology
Casper Webers, Uta Kiltz, Juergen Braun, Desiree van der Heijde, Annelies Boonen
Summary: Treating active SpA improves depressive symptoms, especially with TNF inhibitors (TNFis) which have a stronger effect mainly due to their impact on disease activity.
Article
Rheumatology
Rosalinde Stal, Sofia Ramiro, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Rosaline van den Berg, Desiree van der Heijde, Floris A. van Gaalen
Summary: The objective of this study was to assess the construct validity of the CT Syndesmophyte Score (CTSS) for measuring structural spinal damage in patients with radiographic axial spondyloarthritis. The study compared the scores of CTSS and modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) in detecting syndesmophytes and their correlation with spinal mobility. The results demonstrated good agreement between CTSS and mSASSS in detecting syndesmophytes, and higher correlation of CTSS with spinal mobility measures.
Article
Rheumatology
Mary Lucy Marques, Nuno Pereira da Silva, Desiree van der Heijde, Rosalinde Stal, Xenofon Baraliakos, Juergen Braun, Monique Reijnierse, Caroline Bastiaenen, Sofia Ramiro, Floris A. van Gaalen
Summary: The study investigated the association between inflammation and lower trabecular bone density (TBD) in radiographic axial spondyloarthritis (r-axSpA), and whether a lower TBD increases the likelihood of 2-year bone formation at the same vertebra. The study found that inflammation was associated with lower TBD, but lower TBD itself did not increase the risk of new bone formation at the same vertebra.
Article
Rheumatology
Robert Landewe, Luna Sun, Yun-Fei Chen, Daojun Mo, Desiree van der Heijde
Summary: Demonstrating the inhibition of joint damage in rheumatoid arthritis trials is commonly achieved through statistically significant differences in radiographic progression measured by the mTSS. The frequently used ANCOVA+LE method for handling missing data may not be ideal for long-term extension or paediatric studies. The RC model shows better performance in terms of bias, RMSE, power and type I error rate, making it a more sensitive and precise alternative for analysing mTSS in studies with missing data.
Article
Rheumatology
Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M. Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten, Lianne S. Gensler
Summary: Bimekizumab (BKZ), a monoclonal antibody that inhibits IL-17F and IL-17A, demonstrated sustained efficacy in patients with axial spondyloarthritis (axSpA) at Week 52. The dual inhibition of IL-17A and IL-17F resulted in significant improvements compared to placebo and the safety profile was consistent with previous findings.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Tsutomu Takeuchi, Megumi Nakanishi, Masafumi Kawanishi, Hironori Yamasaki, Yoshiya Tanaka
Summary: This article evaluates the efficacy and safety of extending the dosing interval of ozoralizumab from every 4 weeks to every 8 weeks in patients with rheumatoid arthritis (RA). The results indicate that extending the dosing interval is effective and well tolerated in patients maintaining a disease activity score below 3.2.
MODERN RHEUMATOLOGY
(2023)
Editorial Material
Rheumatology
Marc Feldmann, Ravinder N. Maini, Enrique R. Soriano, Vibeke Strand, Tsutomu Takeuchi
Summary: In this Viewpoint article, five rheumatology researchers discuss how biologic therapy has transformed clinical practice and reflect on their own experiences, past and current challenges, and the future prospects of biologic drugs.
NATURE REVIEWS RHEUMATOLOGY
(2023)
Article
Rheumatology
Rosalinde Stal, Sofia Ramiro, Desiree van der Heijde, Floris A. van Gaalen, Xenofon Baraliakos, Pedro M. Machado, Manouk de Hooge, Rosaline van den Berg, Monique Reijnierse, Juergen Braun, Robert Landewe, Alexandre Sepriano
Summary: In patients with radiographic axial spondyloarthritis, vertebral corner inflammation can lead to the development of syndesmophytes, but only a small portion of this effect is explained by vertebral corner fat deposition.
Article
Rheumatology
Tsutomu Takeuchi, Yukihiro Chino, Masafumi Kawanishi, Megumi Nakanishi, Hirotaka Watase, Yoko Mano, Yuri Sato, Saeko Uchida, Yoshiya Tanaka
Summary: This study aimed to analyze the pharmacokinetics (PK) of Ozoralizumab (OZR) and its correlation with clinical efficacy in rheumatoid arthritis (RA) patients. The results showed that the maximum plasma concentration (C-max) of OZR was reached in 6 days, with a half-life of 18 days. The exposure of OZR correlated negatively with patient body weight and was not significantly affected by other patient baseline characteristics. The efficacy of OZR was sustained independent of trough concentration when administered subcutaneously at a dose of 30 mg every 4 weeks for 52 weeks.
ARTHRITIS RESEARCH & THERAPY
(2023)
